Cold chain News and Research

RSS

Emergent BioSolutions receives NIAID funding support for dmPA7909 anthrax vaccine candidate

Emergent BioSolutions Inc. announced today that it was awarded a cooperative agreement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to further the development of one of Emergent’s advanced anthrax vaccine candidates known as dmPA7909.

30 Sep 2009

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

21 Sep 2009

rPA anthrax vaccine and its Valortim anthrax anti-toxin program data presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.

4 Sep 2009

Bavarian Nordic begins negotiations with U.S. to secure a contract to develop a freeze-dried version of smallpox vaccine

Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine.

25 Aug 2009

Sanofi Pasteur inaugurates high-tech vaccine production facility in France

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the inauguration of a high-tech vaccine production facility in France to respond to soaring demand worldwide.

25 Jun 2008

PharmAthene signs agreement to acquire biodefense vaccines business from Avecia

PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threats, and Avecia Biologics Limited, a contract manufacturer of biopharmaceuticals, has announced that the companies have entered into a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia's biodefense vaccines business.

24 Mar 2008

Measles Initiative exceeds goals

Measles deaths have fallen by 60% worldwide since 1999 - a major public health success. This exceeds the United Nations goal to halve measles deaths between 1999 and 2005 and is largely due to an unprecedented decline in measles deaths in the African region.

22 Jan 2007

WHO tackles rabies, snake bites and scorpion stings

Although more than 12 million people each year are bitten by dogs or snakes, or stung by scorpions, the world's capacity to treat them is inadequate.

9 Jan 2007

Vaccination with irradiated Listeria induced protective T cell immunity

Vaccines made with bacteria killed by gamma irradiation, rather than by standard methods of heat or chemical inactivation, may be more effective, say researchers.

26 Jul 2006

RxKinetix receives grant to develop thermostable vaccines with improved stability at non-refrigerated temperatures

RxKinetix Inc., a specialty pharmaceutical company has received a grant offer from the prestigious Grand Challenges in Global Health initiative. The grant will be used to develop thermostable vaccines with improved stability at non-refrigerated temperatures for use in the world's poorest countries.

30 Jun 2005

Fear of botulism as a bioterrorist weapon is to be reduced by British vaccine technology

Fear of botulism as a bioterrorist weapon is to be reduced, as the US government announces its support for a new British vaccine technology, which promises for the first time to provide an effective defence against botulism – the most deadly naturally occurring substance.

28 Feb 2005

Stable liquid technology will enable vaccines to be stored for long periods without refrigeration and reconstitution

A UK vaccine technology that is set to revolutionise the industry has received £950k funding from the Department for International Development (DFID) to bring to production a pentavalent childhood vaccine that can be stored without refrigeration.

25 Oct 2004

Botswana begins massive emergency polio campaign

The Minister of Health of Botswana today kicked off a massive emergency immunization campaign in the southern African nation of Botswana, following the re-introduction of poliovirus into the country from Nigeria in February.

10 May 2004

PAHO's revolving fund for immunization

A quarter century ago, the Pan American Health Organization (PAHO) and its member countries launched a unique procurement and financing mechanism to buy vaccines, syringes, and "cold chain" equipment – the basic components of their immunization programs.

21 Apr 2004